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SARS-CoV-2 variants and ending the COVID-19 pandemic  
 
The COVID-19 pandemic has devastated health care systems, shut down schools and communities, and 
plunged the world into an economic recession. While 2020 was a challenging year, 2021 looks to be difficult 
with the emergence of multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The 
race to vaccinate the world will need to respond to the pathogen’s constant evolution to evade immunity. 
What marks the path to the end of this pandemic? 
2020 saw the successful development and testing of COVID-19 vaccines within timeframes not considered 
possible before. Two mRNA COVID-19 vaccines produced the first results, with impressive efficacy (94–
95%).1,2 A disadvantage of these two vaccines is their low temperature storage requirements. Although 
other COVID-19 vaccines developed to date that use viral vectors, subunit particles, or inactivated viruses 
have comparatively lower levels of efficacy, with estimates of 70% for ChAdOx1 nCoV-193 and 92% for Gam-
COVID-Vac (Sputnik V)4  adenovirus vector vaccines, they do not have storage temperature requirements 
of the mRNA vaccines and are therefore easier to deliver. Data available so far for COVID-19 vaccines have 
shown protection only against clinical forms of infection, with the exception of recent data showing 
reduction in the duration of viral shedding and viral load among ChAdOx1 nCoV-19 vaccine recipients 
compared with placebo recipients, suggesting potential impact on viral transmission as well.5 
In December, 2020, an unexpected rise in reported COVID-19 cases was attributed to the emergence of the 
new SARS-CoV-2 variants 501Y.V1 (B.1.1.7) in the UK and 501Y.V2 (B.1.351) in South Africa.6,7 In South Africa, 
high transmission in the context of high population immunity8 might have favoured the emergence and 
subsequent spread of the variant. Both variants had a mutation (N501Y) in the receptor-binding domain of 
the spike protein, reported to contribute to increased transmission,9 with estimates ranging between 40% 
and 70% for increased transmission.6 The 501Y.V2 variant has two additional mutations (E484K and K417N) 
in the spike protein that confer a potential immune escape to antibodies.10 In a concerning development, 
another set of mutations (N501Y, E484K, and K417T) in a new P.1 (501Y.V3) lineage has been identified in 
Manaus, Brazil.11 
A key issue is whether COVID-19 vaccines will be able to protect against infection or disease from these new 
SARS-CoV-2 variants. Preliminary research suggests sera from individuals immunised with the mRNA COVID-
19 vaccines neutralise a 501 mutation pseudovirion, but neutralise a 501-484-417 mutant pseudovirion to a 
lesser extent.12 Moreover, preliminary clinical trial results of ChAdOx1nCoV-19 showed 74% efficacy in the UK3 
but only 22% in South Africa,13 whereas NVX-CoV2373, a protein-based COVID-19 vaccine, showed 89% 
efficacy in the UK but only 49% efficacy in South Africa, where the 501Y.V2 variant predominates.14 Similarly, 
differences in vaccine efficacy in the USA and South Africa (72% vs 57%) were reported for the Ad26COV2.S 
COVID-19 vaccine.15 More encouragingly, 85% protection against severe COVID-19 has been reported for the 
Ad26COV2.S vaccine in South Africa, although we do not know the precision around the estimate provided in 
the press release.16 If confirmed, a vaccine strategy targeting first those at risk of severe COVID-19 might 
therefore still be effective even in the presence of variants.  
The recent emergence of SARS-CoV-2 variants, after a period of relative viral genetic stability, is a cause 
for concern since multiple new escape variants could emerge in future and lead to severe epidemic 
rebound, as seen in South Africa. Increased viral transmission creates greater opportunities for the 
emergence of SARS-CoV-2 variants. Hence, the end of the pandemic is only possible when vaccines that 
are effective against circulating variants are distributed equitably across the world. As high-income 
countries race to immunise their populations within months, they leave themselves vulnerable to SARS-
CoV-2 evolving in other countries to a new strain or mutation that vaccines might not protect well against. 
Repeatedly formulating new vaccines may be needed to control some new SARS-CoV-2 variants. With the 
increase in basic reproduction number of more transmissible SARS-CoV-2 variants,6 higher vaccine coverage 
will be required to achieve herd immunity, and vaccinating children might also be necessary to reach this 
coverage.  
The emergence of new SARS-CoV-2 variants calls for a number of important measures (panel). First, fewer 
new infections means less viral replication, which, in turn, lowers the risk of new variants. This situation can 
only be achieved by a combination of non-pharmaceutical interventions and scale-up of vaccines, both being 
important, until population immunity is achieved. Aiming for a COVID-19 elimination strategy is the 
preferred option in this context. 
Second, for surveillance of the circulation of SARS-CoV-2 variants, sharing of variant-specific PCR primers 
could help to monitor their spread, particularly in resource-limited countries. In addition, every country should 
include viral genomic sequencing of SARS-CoV-2 variants in their plans. For resource-limited countries, support 
from WHO, the Africa Centres for Disease Control and Prevention, and other partner institutions will be 
necessary to support expertise and develop capacity as well as strengthen health systems. All genetic 
sequences should be posted on international platforms such as GISAID for shared analyses. Infections in people 
who were previously infected or vaccinated should be carefully examined for escape variants. 
Third, a central repository of samples of sera and cells from individuals with past infection or past 
immunisation with available COVID-19 vaccines should be established for seroneutralisation and cellular 
immunity functional testing against newly discovered variants. This repository could release regular 
advisories to provide guidance on a minimum set of epitopes to be included in new COVID-19 vaccines. 
Fourth, the production of COVID-19 vaccines should be reactive and adapted to newly emerging strains. 
This flexibility is likely to be easier to achieve with the new COVID-19 vaccine technologies currently being 
deployed and based on nucleic acids (mRNA vaccines or viral vector vaccines).17 
Finally, vaccines need to be available, affordable, and accessible at a global scale. Several high-income 
countries have purchased vaccine doses, sometimes close to nine doses per person,18 while WHO has called 
for greater equity and stronger support for the COVAX initiative and its mandate of equitable vaccine access, 
especially for resource-limited countries. Of note is also an initiative of the African Union to independently 
purchase and distribute COVID-19 vaccines to countries over the continent to supplement the COVAX 
programme19 [A: did you want any addition here? ] Done Whether vaccine delivery should be prioritised to 
countries with high SARS-CoV-2 prevalence and continued transmission—eg, South Africa, Brazil, Mexico, or 
India—to prevent further emergence of new variants has to be considered. 
This pandemic is a reminder to high-income countries that infectious diseases have a tremendous impact 
on economies and lives, and rapid development and implementation of effective vaccines against these 
diseases should remain priorities globally. Global cooperation to ensure equity and responsiveness to local 
contexts is essential on the difficult path ahead to ending the COVID-19 pandemic.  
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Panel: Priorities to address new SARS-CoV-2 variants [A:add title for panel] This title is fine 
• Continue to suppress and push to eliminate SARS-CoV-2 while rolling out COVID-19 vaccines 
• Improve surveillance of SARS-CoV-2 variants through global sequencing and sharing of variant-
specific PCR primers 
• Create a central repository of samples of sera and cells from individuals with past infection or past 
immunisation with available COVID-19 vaccines for seroneutralisation and cellular immunity functional 
testing against newly discovered variants 
• Produce COVID-19 vaccines reactively and adapt them to newly emerging strains 
• Ensure global access, availability, and affordability of COVID-19 vaccines to ensure no countries are 
left behind.  
 
